Bromocryptine therapy in cases of amenorrhea-galactorrhea.
Of 28 patients presenting with amenorrhea-galactorrhea, pituitary tumors were confirmed in eight. Six patients had occult hypothyroidism and the rest had an endocrine profile suggestive of pituitary tumor or of an idiopathic etiology. Treatment with bromocryptine resulted in suppression of the inappropriate lactation and restoration of regular menstrual function. In five cases, however, the galactorrhea was only diminished and in four of these cases, normal ovarian function did not return. Of the 19 patients that were seeking fertility and continued the medication for at least 20 days, nine pregnancies resulted. A similar response to bromocryptine was observed regardless of the underlying cause of the amenorrhea-galactorrhea.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D001971:Bromocriptine / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005687:Galactorrhea / Q000188:drug therapy*; D006801:Humans; D007037:Hypothyroidism / Q000150:complications; D007775:Lactation Disorders / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D010911:Pituitary Neoplasms / Q000150:complications; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D013972:Thyrotropin / Q000097:blood
D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin